Metraipolis › archive › dc_5264c7dda1ea

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study — Europe PMC PMID:42396447

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42396447
DOI
10.3389/fimmu.2026.1857350
License (as archived)
solo-consultazione
Archived
2026-10-19T08:12:03.904Z
SHA-256 of the archived text
fd681b231ac0bdaf22f0478858413c67a163f7c398180d6a71f3c46de35b81ee
Stable URL of this page
https://metraipolis.com/documento/dc_5264c7dda1ea

How to cite

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study — Europe PMC PMID:42396447 — Europe PMC (en), https://europepmc.org/article/MED/42396447 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5264c7dda1ea (Metraipolis archive dc_5264c7dda1ea, sha256 fd681b231ac0bdaf22f0478858413c67a163f7c398180d6a71f3c46de35b81ee)
BibTeX
@misc{dc5264c7dda1ea,
  title = {Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study — Europe PMC PMID:42396447},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42396447},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5264c7dda1ea; sha256 fd681b231ac0bdaf22f0478858413c67a163f7c398180d6a71f3c46de35b81ee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42396447. Agents can read the archived copy with the MCP tool read_document.